Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States

These clinical considerations provide information to healthcare professionals and public health officials on use of COVID-19 vaccines. They are informed by:

• Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC)
• COVID-19 vaccine approval (licensure) under a Biologics License Application (BLA) or authorization under an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA)
• CDC’s Emergency Use Instructions (EUI) for FDA-approved vaccines
• The World Health Organization’s (WHO) Emergency Use Listing (EUL) or Prequalification of COVID-19 vaccines
• ACIP’s General Best Practice Guidelines for Immunization

Two types of COVID-19 vaccines are recommended for use in the United States:

• mRNA vaccines
  • Moderna COVID-19 Vaccine (2024–2025 Formula) is authorized for children ages 6 months–11 years; SPIKEVAX is the licensed Moderna product for people ages 12 years and older. These vaccines are hereafter referred to as 2024–2025 Moderna COVID-19 Vaccine.
  • Pfizer-BioNTech COVID-19 Vaccine (2024–2025 Formula) is authorized for children ages 6 months–11 years; COMIRNATY is the licensed Pfizer-BioNTech product for people ages 12 years and older. These vaccines are hereafter referred to as 2024–2025 Pfizer-BioNTech COVID-19 Vaccine.

• Protein subunit vaccine
  • Novavax COVID-19 Vaccine, Adjuvanted (2023–2024 Formula) is authorized for people ages 12 years and older. It is hereafter referred to as 2023–2024 Novavax COVID-19 Vaccine. The 2023–2024 Novavax COVID-19 Vaccine is no longer available for use in the United States as all doses have expired.

There is no preferential recommendation for the use of any one COVID-19 vaccine over another when more than one recommended and age-appropriate vaccine is available.

2024-2025 mRNA COVID-19 vaccine composition

The 2024–2025 formulation for Moderna and Pfizer-BioNTech COVID-19 vaccines approved and authorized in the United States has been updated to a monovalent vaccine based on the Omicron JN.1-lineage of SARS-CoV-2, KP.2.

COVID-19 vaccine-specific package inserts and EUA fact sheets for healthcare providers (fact sheets) and U.S. COVID-19 Vaccine Product Information can be consulted for a full list of ingredients and information on the conditions of use, storage and handling, preparation, and administration procedures.

Groups recommended for vaccination

COVID-19 vaccination is recommended for everyone ages 6 months and older in the United States for the prevention of COVID-19. There is currently no FDA-approved or FDA-authorized COVID-19 vaccine for children younger than age 6 months.

CDC recommends that people receive all recommended COVID-19 vaccine doses. Vaccination is especially important for people at highest risk of severe COVID-19, including people ages 65 years and older; people with underlying medical conditions, including immune compromise; people living in long-term care facilities; and pregnant people to protect themselves and their infants.

Vaccine dosage and administration

General Best Practice Guidelines for Immunization apply to COVID-19 vaccination unless otherwise noted. People should receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination and follow the recommended dosing intervals (Table 1 and Table 2).

COVID-19 vaccine doses should be administered by the intramuscular route.

An overview of the 2024–2025 COVID-19 vaccination schedule for Moderna and Pfizer-BioNTech vaccines is summarized below. Detailed vaccination schedules can be found in Table 1 for people who are not moderately or severely immunocompromised and in Table 2 for people who are moderately or severely immunocompromised. See Appendix A for recommendations for people who received COVID-19 vaccine outside the United States.

Initial vaccination

• Ages 6 months–4 years
  • 2 doses of 2024–­2025 Moderna or 3 doses of 2024–­2025 Pfizer-BioNTech
• Ages 5 years and older
  • 1 dose of 2024–2025 Moderna or 1 dose of 2024–2025 Pfizer-BioNTech

Received previous doses of a COVID-19 vaccine

• Ages 6 months–4 years
  • 1 or 2 doses of 2024–­2025 mRNA vaccine from the same manufacturer as administered for initial vaccination, depending on the vaccine and the number of prior doses
• Ages 5 years and older
  • 1 dose of 2024–­2025 Moderna or 1 dose of 2024–­2025 Pfizer-BioNTech

Additional dose: An additional dose of 2024–2025 COVID-19 vaccine for people ages 65 years and older who are not moderately or severely immunocompromised is NOT currently recommended. ACIP will monitor available data on the epidemiology of COVID-19 and the safety and effectiveness of COVID-19 vaccines, and update COVID-19 vaccination recommendations as needed, including for people ages 65 years and older.

Initial vaccination

• Ages 6 months and older
  • 3 doses of 2024–­2025 Moderna or 3 doses of 2024–­2025 Pfizer-BioNTech

Received previous doses of a COVID-19 vaccine

• Recommended mRNA vaccine and number of 2024–­2025 doses are based on age and vaccination history

Additional doses: People who are moderately or severely immunocompromised ages 6 months and older may receive 1 or more age-appropriate additional doses of a 2024–2025 mRNA COVID-19 vaccine.

The COVID-19 vaccination schedule for people who are not moderately or severely immunocompromised is detailed in Table 1 for 2024–2025 mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech). The recommended vaccine and number of 2024–2025 COVID-19 vaccine doses are based on age and vaccination history.

Table 1. People who are not moderately or severely immunocompromised: Recommended COVID-19 vaccination schedule by COVID-19 vaccination history, August 23, 2024

2024–2025 mRNA vaccines

Ages 6 months–4 years

Ages 5–11 years

Ages 12 years and older

An 8-week interval between the first and second mRNA COVID-19 vaccine (Moderna, Pfizer-BioNTech) doses might be optimal for some people as it might reduce the rare risk of myocarditis and pericarditis associated with these COVID-19 vaccines.

While absolute risk remains small, an elevated risk for myocarditis and pericarditis has been observed among mRNA COVID-19 vaccine recipients, particularly in males ages 12–39 years (see COVID-19 vaccination and myocarditis and pericarditis for additional information). Cases of myocarditis and pericarditis were identified in clinical trials of Novavax COVID-19 Vaccine and through passive surveillance during post-authorization use outside the United States.

Under the current COVID-19 vaccination schedule (Table 1), the extended interval consideration applies only to the following people who are not moderately or severely immunocompromised:

• Ages 6 months–4 years, depending on their vaccination history

The minimum interval between the first and second doses continues to be recommended for:

• People who are moderately or severely immunocompromised
• Situations when the fullest possible protection needs to be achieved sooner (e.g., increased concern about an individual’s higher risk for severe disease)

The COVID-19 vaccination schedule for people ages 6 months and older who are moderately or severely immunocompromised is detailed in Table 2 for 2024–2025 mRNA COVID-19 vaccines. The recommended vaccine and number of 2024–2025 COVID-19 vaccine doses are based on age and vaccination history. In all age groups, COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended; see Interchangeability of COVID-19 vaccines for circumstances in which doses from different manufacturers may be considered.

Additional doses: People who are moderately or severely immunocompromised may receive additional dose(s) of 2024–2025 mRNA COVID-19 vaccine after the last 2024–2025 mRNA COVID-19 vaccine dose indicated in Table 2. For detailed guidance on administration of age-appropriate additional doses, consult Table 2.

For information on the use of pemivibart (Pemgarda™) for COVID-19 pre-exposure prophylaxis, see COVID-19 vaccination and pemivibart.

Table 2. People who are moderately or severely immunocompromised: Recommended COVID-19 vaccination schedule by COVID-19 vaccination history, August 23, 2024

2024–2025 mRNA vaccines

Ages 6 months–4 years

Ages 5–11 years

Ages 12 years and older

Development of moderate or severe immunocompromise after vaccination: People who were vaccinated for COVID-19 and subsequently become moderately or severely immunocompromised should follow the COVID-19 vaccination schedule according to their age and prior COVID-19 vaccination history (Table 2); see Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies for vaccination of people who will shortly become moderately or severely immunocompromised (e.g., prior to organ transplant) and Considerations for COVID-19 revaccination.

Pemivibart (Pemgarda™) is a monoclonal antibody for COVID-19 pre-exposure prophylaxis in people who are moderately or severely immunocompromised and unlikely to mount an adequate immune response to COVID-19 vaccination and who meet the FDA-authorized conditions for use. Pemivibart is not authorized for treatment of COVID-19 or for post-exposure prophylaxis. Healthcare providers should consult the pemivibart EUA fact sheet and EUA frequently asked questions for the FDA-authorized conditions under which pemivibart may be used.

Pemivibart is not a substitute for COVID-19 vaccination. People who are moderately or severely immunocompromised should receive COVID-19 vaccine according to the recommended schedule. Per the pemivibart EUA, administration of pemivibart should be deferred for at least 2 weeks after a dose of COVID-19 vaccine.

Moderate and severe immunocompromising conditions and treatments include but are not limited to:

• Active treatment for solid tumor and hematologic malignancies
• Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia)
• Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy
• Receipt of chimeric antigen receptor (CAR)-T-cell therapy or hematopoietic cell transplant (HCT) (within 2 years of transplantation or taking immunosuppressive therapy)
• Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome)
• Advanced HIV infection (people with HIV and CD4 cell counts less than 200/mm³, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) or untreated HIV infection
• Active treatment with high-dose corticosteroids (i.e., 20 mg or more of prednisone or equivalent per day when administered for 2 or more weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor necrosis factor (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell-depleting agents)

Factors to consider in assessing the general level of immune competence in a patient include disease severity, duration, clinical stability, complications, comorbidities, and any potentially immune-suppressing treatment.

For additional information about the degree of immune suppression associated with different medical conditions and treatments, providers can consult ACIP’s General Best Practice Guidelines for Immunizations, the CDC Yellow Book, and the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host.

People can self-attest to their moderately or severely immunocompromised status and receive COVID-19 vaccine doses wherever vaccines are offered. Vaccinators should not deny COVID-19 vaccination to a person due to lack of documentation.

Recipients of HCT or CAR-T-cell therapy who received 1 or more doses of COVID-19 vaccine prior to or during treatment should be revaccinated. Revaccination should start at least 3 months (12 weeks) after transplant or CAR-T-cell therapy and should follow the currently recommended schedule for people who are unvaccinated (Table 2).

Revaccination may also be considered for patients who received 1 or more doses of COVID-19 vaccine during treatment with B-cell-depleting therapies (e.g., rituximab, ocrelizumab) that were administered over a limited period (e.g., as part of a treatment regimen for certain malignancies) according to the currently recommended schedule (Table 2). The suggested interval to start revaccination is about 6 months after completion of the B-cell-depleting therapy. Timing of vaccination for patients who receive B-cell-depleting therapies on a continuing basis (e.g., for treatment of certain autoimmune conditions such as rheumatoid arthritis or multiple sclerosis) is addressed in Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies.

A patient’s clinical team is best positioned to determine the degree of immune compromise, need for revaccination, and appropriate timing of revaccination.

Administration of COVID-19 vaccines should not be delayed in patients taking immunosuppressive therapies. Whenever possible, COVID-19 vaccines should be administered at least 2 weeks before initiation or resumption of immunosuppressive therapies. For patients who receive B-cell-depleting therapies on a continuing basis, COVID-19 vaccines should be administered approximately 4 weeks before the next scheduled therapy.

Timing of COVID-19 vaccination should take into consideration:

• Current or planned immunosuppressive therapies
• Optimization of both the patient’s medical condition and anticipated response to vaccination
• Individual benefits and risks

On a case-by-case basis, providers caring for these patients may administer Moderna and Pfizer-BioNTech COVID-19 vaccines outside of the FDA and CDC dosing intervals when, based on their clinical judgment, the benefits of vaccination are deemed to outweigh the potential and unknown risks for the recipient who is immunocompromised.

The utility of serologic testing, cellular immune testing, or B-cell quantification to assess immune response to vaccination and guide clinical care has not been established. Such testing outside of the context of research studies is not recommended at this time.

CDC recommends that people receive the age-appropriate vaccine product and dosage based on their age on the day of vaccination (Table 1 and Table 2).

If a person moves to an older age group between vaccine doses, they should receive the vaccine product and dosage for the older age group. For children who transition from age 4 years to age 5 years and children who are moderately or severely immunocompromised and transition from age 11 years to age 12 years, the option to administer a lower dosage is no longer authorized (see Table 1 and Table 2).

Routine administration of all age-appropriate doses of vaccines simultaneously, also known as coadministration, is recommended for children, adolescents, and adults if there are no contraindications at the time of the healthcare visit. Providers may simultaneously administer COVID-19, influenza, and respiratory syncytial virus (RSV) vaccines to eligible patients; additional information about simultaneous administration of these vaccines is available.

There are additional considerations for simultaneous administration of an orthopoxvirus vaccine and COVID-19 vaccine as follows:

• There is no required minimum interval between receiving a dose of any COVID-19 vaccine and an orthopoxvirus vaccine, either JYNNEOS or ACAM2000 vaccine (e.g., for mpox prevention), regardless of which vaccine is administered first.
• Use of JYNNEOS vaccine should be prioritized over ACAM2000 when co-administering a COVID-19 vaccine and an orthopoxvirus vaccine.
• People, particularly adolescent or young adult males, who are recommended to receive both vaccines might consider waiting 4 weeks between vaccines. This is because of the observed risk for myocarditis and pericarditis after receipt of ACAM2000 orthopoxvirus vaccine and COVID-19 vaccines, and the hypothetical risk for myocarditis and pericarditis after JYNNEOS vaccine. However, if a patient’s risk for mpox or severe disease due to COVID-19 is increased, administration of mpox and COVID-19 vaccines should not be delayed.

Nirsevimab: Simultaneous administration of COVID-19 vaccine and nirsevimab (a long-acting monoclonal antibody indicated for certain infants and young children for prevention of RSV lower respiratory tract disease) is recommended.

For best practices for administering multiple injections, see ACIP General Best Practice Guidelines for Immunization and Epidemiology and Prevention of Vaccine-Preventable Diseases (Pink Book).

Administration of COVID-19 vaccine doses from different manufacturers

COVID-19 vaccine doses from the same manufacturer should be administered whenever recommended. In the following circumstances, an age-appropriate COVID-19 vaccine from a different manufacturer may be administered:

• Same vaccine not available at the time of the clinic visit
• Previous dose unknown
• Person would otherwise not receive a recommended vaccine dose
• Person starts but unable to complete a vaccination series with the same COVID-19 vaccine due to a contraindication

A Vaccine Adverse Event Reporting System (VAERS) report is not indicated in these circumstances.

mRNA COVID-19 vaccines

If mRNA vaccine doses are administered from different manufacturers because of a circumstance described above, a 3-dose schedule should be followed:

Children ages 6 months–4 years

• The second dose is administered 4–8 weeks after the first dose.
• The third dose of either 2024–2025 Moderna vaccine or 2024–2025 Pfizer-BioNTech vaccine is administered at least 8 weeks after the second dose.

People ages 6 months and older who are moderately or severely immunocompromised

• The second dose is administered 4 weeks after the first dose.
• The third dose of either 2024–2025 Moderna vaccine or 2024–2025 Pfizer-BioNTech vaccine is administered as follows:

• • Ages 6 months–4 years: at least 8 weeks after the second dose
  • Ages 5 years and older: at least 4 weeks after the second dose

See Appendix B for additional information if doses from different manufacturers are administered for initial vaccination.

Antibody testing is not currently recommended to assess the need for vaccination in an unvaccinated person or to assess immunity to SARS-CoV-2 following COVID-19 vaccination or SARS-CoV2 infection. If antibody testing is done, vaccination should proceed as recommended regardless of the antibody test result.

COVID-19 vaccination will not affect the results of SARS-CoV-2 viral tests (nucleic acid amplification or antigen tests).

For more information see  Overview of Testing for SARS-CoV-2 and the FDA Web page on serologic testing.

Providers should counsel COVID-19 vaccine recipients, parents, or guardians about expected local and systemic reactions.

• Local reactions include pain/tenderness, and, less commonly, swelling and redness at the injection site.
• Systemic reactions include fever, fatigue/malaise, headache, chills, myalgia, arthralgia, and diarrhea; among younger children, particularly those younger than age 3 years, systemic reactions also can include irritability/crying, sleepiness, and loss of appetite.

Localized axillary lymphadenopathy on the same side as the vaccinated arm or groin, if vaccination was in the thigh, has been observed following vaccination with Moderna, Novavax, and Pfizer-BioNTech COVID-19 vaccines. Infrequently, people who have received dermal fillers might experience temporary swelling at or near the site of filler injection (usually face or lips) following a dose of an mRNA COVID-19 vaccine.

Myocarditis and pericarditis: People receiving any COVID-19 vaccine, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following COVID-19 vaccination and the option for an extended interval between doses. Counseling should include the need to seek care if symptoms of myocarditis or pericarditis develop after vaccination, particularly in the week after vaccination. See COVID-19 vaccination and myocarditis and pericarditis for additional information.

Anaphylactic reactions: Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines. For more information on the assessment and potential management of anaphylaxis, see Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination.

For more information on patient counseling, see Vaccine Recipient Education.

Syncope (fainting) might occur in association with any injectable vaccine, especially in adolescents. In accordance with General Best Practice Guidelines for Immunization, vaccination providers, particularly when vaccinating adolescents, should consider observing vaccine recipients for 15 minutes after vaccination.

Additionally, to monitor for allergic reactions, providers should consider observing people with the following precautions to a previously administered COVID-19 vaccine type for 30 minutes if a subsequent dose of the same vaccine type is administered:

• History of a non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type
• History of a diagnosed non-severe allergy to a component of the COVID-19 vaccine

See Contraindications and precautions for more information.

CDC considers the conditions listed in Table 3 to be COVID-19 vaccination contraindications and precautions.

Table 3. Contraindications and precautions to COVID-19 vaccination

People with a contraindication to one COVID-19 vaccine type (Table 3) may receive the alternative COVID-19 vaccine type in the usual vaccination setting. Consultation with an allergist-immunologist is encouraged to provide expert evaluation of the original allergic reaction, and depending on the outcome of the evaluation, reassess if administration of additional doses of the same vaccine type may be possible.

People with an allergy-related precaution to one COVID-19 vaccine type (Table 3) may receive the alternative COVID-19 vaccine type in the usual vaccination setting. Vaccination with the same COVID-19 vaccine type may be considered on an individual basis; the same vaccine type should be administered in an appropriate setting and under the supervision of a health care provider experienced in the management of severe allergic reactions.  An observation period of 30 minutes post-vaccination should be considered. Referral to an allergist-immunologist should be considered.

Healthcare professionals and health departments may request a consultation from CDC’s Clinical Immunization Safety Assessment COVIDvax project for a complex COVID-19 vaccine safety question not readily addressed by CDC guidance.

For licensed COVID-19 vaccines (Moderna and Pfizer-BioNTech in people ages 12 years and older), healthcare providers are strongly encouraged to report to VAERS:

• Any adverse event that occurs after the administration of a vaccine licensed in the United States, whether or not it is clear that a vaccine caused the adverse event
• Vaccine administration errors, whether or not associated with an adverse event

For COVID-19 vaccines given under an EUA, vaccination providers are required to report to VAERS:

• Vaccine administration errors, whether or not associated with an adverse event
• Serious adverse events regardless of causality. Serious adverse events per FDA are defined as:
  • Death
  • A life-threatening adverse event
  • Inpatient hospitalization or prolongation of existing hospitalization
  • A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
  • A congenital anomaly/birth defect
  • An important medical event that based on appropriate medical judgement may jeopardize the individual and may require medical or surgical intervention to prevent one of the outcomes listed above
• Cases of Multisystem Inflammatory Syndrome (MIS) in children and adults
• Cases of myocarditis
• Cases of pericarditis
• Cases of COVID-19 that result in hospitalization or death

Reporting is also encouraged for any other clinically significant adverse event, even if it is uncertain whether the vaccine caused the event.

Information on how to submit a report to VAERS is available at https://vaers.hhs.gov or by calling 1-800-822-7967. In addition, anyone can register in V-safe after their COVID-19 vaccination to receive health check-ins via text messages or email.

In clinical trials of Moderna and Pfizer-BioNTech COVID-19 vaccines, types of post-vaccination reactions were generally similar. However, the frequency of some reactions varied by age, vaccine manufacturer, and vaccine dose. The most frequent reported reactions, by age group, follow below.

People ages 12 years and older

• Local: Injection site pain; less commonly, injection site redness and swelling, and axillary swelling/tenderness

• Systemic: Fatigue, headache, myalgia, arthralgia, and chills; less commonly, fever and nausea/vomiting

Overall, symptoms tended to be more frequent and severe following the second dose of vaccine and among adolescents and younger adults compared with older adults.

Children ages 6 months–11 years

• Local: Injection site pain/tenderness; less commonly, injection site redness and swelling, and axillary or groin swelling/tenderness
• Systemic:
  • Ages 6 months–4 years: Irritability/crying, drowsiness/sleepiness, and decreased/loss of appetite, particularly in children younger than age 3 years; less commonly, fever
  • Ages 5–11 years: Fatigue and headache; less commonly, myalgia, arthralgia, fever, chills, diarrhea, and nausea/vomiting

In all age groups, most symptoms were mild to moderate in severity, typically began 1–2 days after vaccination, and resolved after 1–3 days.

EUA fact sheets and package inserts can be consulted for detailed information about post-vaccination reactions for Moderna and Pfizer-BioNTech COVID-19 vaccines.

Febrile seizures in infants and young children occur infrequently after any vaccination; one febrile seizure was reported among participants ages 6 months–23 months in Moderna’s COVID-19 clinical trial. CDC postmarketing safety surveillance for mRNA COVID-19 vaccines has not identified a safety concern for febrile seizure in children ages 6 months–5 years. The potential impact of simultaneous administration of COVID-19 and routine vaccines on the risk of febrile seizures has not been specifically studied. CDC is continuing to monitor for febrile seizures following COVID-19 vaccination in infants and young children.

See also COVID-19 vaccination and myocarditis and pericarditis.

In clinical trials of Novavax COVID-19 Vaccine among people ages 12 years and older, the most frequent reported vaccine reactions included:

• Local: Pain/tenderness at the injection site; less commonly, redness and swelling
• Systemic: Fatigue/malaise, headache, and myalgia; less commonly, arthralgia, nausea/vomiting, and fever

In addition, lymphadenopathy was also reported to occur after Novavax vaccination in the clinical trials.

Most symptoms were mild to moderate in severity, had onset 1-3 days after vaccination, and resolved within 1–3 days. Overall, symptoms were more frequent in people ages 12–64 years compared to people ages 65 years and older and more frequent after dose 2 than dose 1 of the initial vaccination series.

The EUA fact sheet can be consulted for detailed information about post-vaccination reactions for Novavax COVID-19 Vaccine.

See also COVID-19 vaccination and myocarditis and pericarditis.

Cases of myocarditis and pericarditis have rarely been observed following receipt of COVID-19 vaccines used in the United States.

Evidence from multiple monitoring systems in the United States and globally support a causal association for mRNA COVID-19 vaccines (Moderna or Pfizer-BioNTech) and myocarditis and pericarditis. Cases have occurred most frequently in adolescent and young adult males within 7 days after receiving the second dose of an mRNA COVID-19 vaccine (Moderna and Pfizer-BioNTech); however, cases have also been observed in females and after other doses. Data from clinical trials of Novavax COVID-19 Vaccine and post-authorization vaccine safety monitoring outside the United States suggest an increased risk of myocarditis and pericarditis following Novavax vaccination.

For mRNA COVID-19 vaccines and Novavax COVID-19 Vaccine:

• After reviewing available data, ACIP and CDC determined that the benefits of COVID-19 vaccination (e.g., prevention of COVID-19 and its severe outcomes) outweigh the rare risk of myocarditis and pericarditis in all populations recommended for vaccination.
• Extending the interval to 8 weeks between the first and second doses for some people might reduce the rare risk of vaccine-associated myocarditis and pericarditis; see Considerations for extended intervals for COVID-19 vaccination for more information.
• People, especially males ages 12–39 years, should be made aware of the rare risk of myocarditis and pericarditis following receipt of these vaccines; the option for an extended interval between doses; and the benefit of COVID-19 vaccination in reducing the risk of severe outcomes from COVID-19, including the possibility of cardiac sequelae.
  • Counseling should include the need to seek care if symptoms of myocarditis or pericarditis, such as chest pain, shortness of breath, or palpitations develop after vaccination, particularly in the week after vaccination.
  • In younger children, symptoms of myocarditis might also include non-specific symptoms such as irritability, vomiting, poor feeding, tachypnea, or lethargy.

For people who have a history of myocarditis associated with MIS-C or MIS-A, see COVID-19 vaccination and MIS-C and MIS-A.

Myocarditis or pericarditis after a dose of COVID-19 vaccine

Development of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine, and subsequent doses should generally be avoided. Experts advise that these people should:

• Generally not receive a subsequent dose of any COVID-19 vaccine
• If, after a risk assessment, the decision is made to administer a subsequent COVID-19 vaccine dose, wait until at least their episode of myocarditis or pericarditis has resolved (resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by patient’s clinical team)

Considerations for subsequent COVID-19 vaccination might include:

• Myocarditis or pericarditis considered unrelated to vaccination (e.g., due to SARS-CoV-2 or other viruses)
• Personal risk of severe acute COVID-19 (e.g., age, underlying conditions)
• Timing of any immunomodulatory therapies; ACIP’s General Best Practice Guidelines for Immunization can be consulted for more information

History of myocarditis or pericarditis that occurred prior to COVID-19 vaccination or more than 3 weeks after a COVID-19 vaccine dose

People who have a history of myocarditis or pericarditis that occurred before COVID-19 vaccination or more than 3 weeks after a COVID-19 vaccine dose may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine after the episode of myocarditis or pericarditis has completely resolved (i.e., resolution of symptoms, no evidence of ongoing heart inflammation or sequelae as determined by the person’s clinical team). This includes people who had myocarditis or pericarditis due to SARS-CoV-2 or other viruses.

History of other heart disease

People who have a history of other heart disease, including congenital heart disease and Kawasaki disease, may receive any currently FDA-approved or FDA-authorized COVID-19 vaccine.

COVID-19 vaccination is recommended for everyone ages 6 months and older, regardless of prior symptomatic or asymptomatic SARS-CoV-2 infection, including people with Long COVID.

People who recently had SARS-CoV-2 infection may consider delaying a COVID-19 vaccine dose by 3 months from symptom onset or positive test (if infection was asymptomatic). Studies have shown that increased time between infection and vaccination might result in an improved immune response to vaccination. Also, a low risk of reinfection has generally been observed in the months following infection. Individual factors such as risk of COVID-19 severe disease and current indicators of community transmission should be taken into account when determining whether to delay getting a COVID-19 vaccination after infection.

MIS-C is a rare but severe condition in children and adolescents, typically occurring 2-6 weeks after SARS-CoV-2 infection. MIS-A, a similar condition in adults, is even more infrequent and less well characterized. Both include a dysregulated immune response to SARS-CoV-2 infection. The risk of recurrence of MIS following reinfection with SARS-CoV-2 is unknown, although reports of recurrent MIS-C are uncommon.

There have been rare reports of MIS-like illness after COVID-19 vaccination identified from U.S. surveillance (<1 MIS-C case per million vaccinated children without laboratory evidence of SARS-CoV-2 infection). However, the contribution of COVID-19 vaccination to an MIS-like illness is unknown.

Experts consider the benefits of COVID-19 vaccination for people with a history of MIS-C or MIS-A (i.e., a reduced risk of severe disease including potential recurrence of MIS-C after reinfection) to outweigh a theoretical risk of an MIS-like illness or the risk of myocarditis following COVID-19 vaccination for those who meet the following two recovery criteria:

1. Clinical recovery has been achieved, including return to baseline cardiac function; and
2. It has been at least 90 days after the diagnosis of MIS-C or MIS-A

COVID-19 vaccination may also be considered for people who had MIS-C or MIS-A and do not meet both criteria, at the discretion of their clinical care team. Experts view clinical recovery, including return to baseline cardiac function, as an important factor when considering COVID-19 vaccination. Additional factors, such as the risk of severe COVID-19 due to age or certain medical conditions, may also be considered.

The timing of COVID-19 vaccination in people with a history of MIS-C or MIS-A should take into consideration current or planned immunomodulatory therapies for treatment of MIS-C or MIS-A; see Considerations for timing of COVID-19 vaccination in relation to immunosuppressive therapies for more information.

Onset of MIS more than 60 days after most recent COVID-19 vaccine dose

Administration of subsequent COVID-19 vaccine doses should be considered for those who meet the two recovery criteria described in Considerations for initiating COVID-19 vaccination in people with a history of MIS-C or MIS-A.

Onset of MIS 60 days or fewer after most recent COVID-19 vaccine dose

For persons in this category who meet the recovery criteria, the decision whether or not to administer subsequent COVID-19 vaccine doses should be made on an individual basis by the clinical care team and patient or parent or guardian. Subsequent COVID-19 vaccine doses should especially be considered if there is strong evidence that the MIS-C or MIS-A was a complication of a recent SARS-CoV-2 infection.

COVID-19 vaccinations is recommended for people who are pregnant, trying to get pregnant now, or who might become pregnant in the future, and people who are breastfeeding. A growing body of evidence on the safety and effectiveness of COVID-19 vaccination indicates that the benefits of vaccination outweigh any potential risks of COVID-19 vaccination during pregnancy. Maternal vaccination has also been shown to be safe and effective, and protects infants younger than age 6 months from severe COVID-19 and hospitalization.

Side effects can occur after COVID-19 vaccination in pregnant people, similar to those among non-pregnant people. Acetaminophen can be offered as an option for pregnant people experiencing fever (fever has been associated with adverse pregnancy outcomes) or other post-vaccination symptoms.